Cattle & Sheep Vaccines

Protect against clostridial diseases such as blackleg and bacterial red water. The primary course of immunization for cattle consists of a 2 ml initial dose followed by a further 2 ml dose six weeks later. Sheep follow the same dosing program but only need a 1ml dose. In areas of high risk of infection from C. haemolyticum infection an initial vaccination regime of two doses of 4 ml is recommended. Revaccination is recommended using 2 - 4 ml, depending on severity of risk of infection from C. haemolyticum, at intervals of not less than one year. Use during pregnancy for passive protection of calves, previously vaccinated pregnant cattle should be vaccinated 2-8 weeks before calving. For an optimum immune response, calves from cows vaccinated during pregnancy should not be vaccinated until 8-12 weeks of age. Zero withdrawal for meat offal and milk. The re-vaccination plan involves a single dose every 6-12 months.

Protect against clostridial diseases such as blackleg and bacterial red water. The primary course of immunization for cattle consists of a 2 ml initial dose followed by a further 2 ml dose six weeks later. Sheep follow the same dosing program but only need a 1ml dose. In areas of high risk of infection from C. haemolyticum infection an initial vaccination regime of two doses of 4 ml is recommended. Revaccination is recommended using 2 - 4 ml, depending on severity of risk of infection from C. haemolyticum, at intervals of not less than one year. Use during pregnancy for passive protection of calves, previously vaccinated pregnant cattle should be vaccinated 2-8 weeks before calving. For an optimum immune response, calves from cows vaccinated during pregnancy should not be vaccinated until 8-12 weeks of age. Zero withdrawal for meat offal and milk. The re-vaccination plan involves a single dose every 6-12 months.

Protect against clostridial diseases such as blackleg and bacterial red water. The primary course of immunization consists of a 2ml initial dose followed by a further 2ml dose six weeks later. In areas of high risk of infection from haemolyticum infection, an initial vaccination regime of two doses of 4ml is recommended. Revaccination is recommended using 2 - 4ml, depending on severity of risk of infection from C. haemolyticum, at intervals of no less than one year. Use during pregnancy for passive protection of calves, previously vaccinated pregnant cattle should be vaccinated 2-8 weeks before calving. For an optimum immune response, calves from cows vaccinated during pregnancy should not be vaccinated until 8-12 weeks of age. Zero withdrawal for meat offal and milk.

Protect against clostridial diseases such as blackleg and bacterial red water. The primary course of immunization consists of a 2ml initial dose followed by a further 2ml dose six weeks later. In areas of high risk of infection from haemolyticum infection, an initial vaccination regime of two doses of 4ml is recommended. Revaccination is recommended using 2 - 4ml, depending on severity of risk of infection from C. haemolyticum, at intervals of no less than one year. Use during pregnancy for passive protection of calves, previously vaccinated pregnant cattle should be vaccinated 2-8 weeks before calving. For an optimum immune response, calves from cows vaccinated during pregnancy should not be vaccinated until 8-12 weeks of age. Zero withdrawal for meat offal and milk.

For administration to pregnant cows and heifers to stimulate serological and colostral antibodies against rotavirus and coronavirus antigens and against K99, Y, 31A and F41 antigens of Escherischia coli in susceptible animals, which may be passed to the calf to reduce neonatal diarrhoea infection caused by agents containing these antigens.

Ewes: • For active immunisation of healthy ewes in flocks with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis (reduction of udder lesions, somatic cell count and S. aureus count) caused by Staphylococcus aureus. Female Goats: • For active immunisation of healthy female goats in herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis caused by Staphylococcus aureus and/or Coagulase-Negative Staphylococci; when clinical mastitis caused by Coagulase-Negative Staphylococci* however occurs, the severity of clinical signs (udder and milk aspect) is reduced. (*Determination of the CNS species has not been performed) Dosage & Administration • Give one dose (2ml) by deep intramuscular injection in the neck muscles at 5 weeks before the expected parturition date and 3 weeks after the first dose administer a second dose. • Allow the vaccine to reach a temperature of 15 - 250C before administration. Shake before use • Minimum age of vaccination; 8 months • The basic vaccination scheme is to be repeated prior to each lactation • The whole flock should be immunised

For active immunisation of pregnant heifers and cows to raise antibodies in their colostrum against Gp40 of Cryptosporidium parvum, intended for passive immunisation of calves to reduce clinical signs (i.e. diarrhoea) caused by C. parvum.

Newborn calves:
Onset of immunity: Passive immunity commences from the start of colostrum feeding. Duration of immunity: In calves that receive colostrum and transition milk as indicated and which were challenged at birth, passive immunity has been demonstrated until 2 weeks of age.

For active immunisation of pregnant heifers and cows to raise antibodies in their colostrum against Gp40 of Cryptosporidium parvum, intended for passive immunisation of calves to reduce clinical signs (i.e. diarrhoea) caused by C. parvum.

Newborn calves:
Onset of immunity: Passive immunity commences from the start of colostrum feeding. Duration of immunity: In calves that receive colostrum and transition milk as indicated and which were challenged at birth, passive immunity has been demonstrated until 2 weeks of age.

Active immunisation of pregnant heifers and cows in order to stimulate the development of antibodies against bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin and to increase the level of passive immunity of calves against neonatal diarrhoea caused by bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin.

In calves fed with colostrum and milk from vaccinated cows for the first week of life, laboratory studies conducted with heterologous challenge strains (a G6 BRV strain, a BCV strain and a K99 E. coli strain) have demonstrated that these antibodies:
-prevent neonatal diarrhoea caused by bovine rotavirus and E. coli expressing F5 (K99) adhesin,
-reduce the incidence and severity of neonatal diarrhoea caused by bovine coronavirus,
-reduce faecal shedding of virus in calves infected with bovine rotavirus and bovine coronavirus.

Onset of immunity:
In calves fed with colostrum from vaccinated heifers or cows, passive immunity commences with colostrum feeding and is dependent on calves receiving sufficient colostrum after birth.

Duration of immunity:
Calves fed with colostrum and milk from vaccinated dams for the first week of life are protected against bovine rotavirus for 7 days and against bovine coronavirus for 14 days. The duration of immunity against infections caused by E. coli expressing F5 (K99) adhesin was not studied since such disease is usually observed in calves less than 3 days of age and susceptibility to enterotoxigenic E.coli is age dependent.

Active immunisation of pregnant heifers and cows in order to stimulate the development of antibodies against bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin and to increase the level of passive immunity of calves against neonatal diarrhoea caused by bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin.

In calves fed with colostrum and milk from vaccinated cows for the first week of life, laboratory studies conducted with heterologous challenge strains (a G6 BRV strain, a BCV strain and a K99 E. coli strain) have demonstrated that these antibodies:
-prevent neonatal diarrhoea caused by bovine rotavirus and E. coli expressing F5 (K99) adhesin,
-reduce the incidence and severity of neonatal diarrhoea caused by bovine coronavirus,
-reduce faecal shedding of virus in calves infected with bovine rotavirus and bovine coronavirus.

Onset of immunity:
In calves fed with colostrum from vaccinated heifers or cows, passive immunity commences with colostrum feeding and is dependent on calves receiving sufficient colostrum after birth.

Duration of immunity:
Calves fed with colostrum and milk from vaccinated dams for the first week of life are protected against bovine rotavirus for 7 days and against bovine coronavirus for 14 days. The duration of immunity against infections caused by E. coli expressing F5 (K99) adhesin was not studied since such disease is usually observed in calves less than 3 days of age and susceptibility to enterotoxigenic E.coli is age dependent.

Active immunisation of pregnant heifers and cows in order to stimulate the development of antibodies against bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin and to increase the level of passive immunity of calves against neonatal diarrhoea caused by bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin.

In calves fed with colostrum and milk from vaccinated cows for the first week of life, laboratory studies conducted with heterologous challenge strains (a G6 BRV strain, a BCV strain and a K99 E. coli strain) have demonstrated that these antibodies:
-prevent neonatal diarrhoea caused by bovine rotavirus and E. coli expressing F5 (K99) adhesin,
-reduce the incidence and severity of neonatal diarrhoea caused by bovine coronavirus,
-reduce faecal shedding of virus in calves infected with bovine rotavirus and bovine coronavirus.

Onset of immunity:
In calves fed with colostrum from vaccinated heifers or cows, passive immunity commences with colostrum feeding and is dependent on calves receiving sufficient colostrum after birth.

Duration of immunity:
Calves fed with colostrum and milk from vaccinated dams for the first week of life are protected against bovine rotavirus for 7 days and against bovine coronavirus for 14 days. The duration of immunity against infections caused by E. coli expressing F5 (K99) adhesin was not studied since such disease is usually observed in calves less than 3 days of age and susceptibility to enterotoxigenic E.coli is age dependent.

For the active immunisation of calves from the age of 10days against bovine respiratory syncytial virus (BRSV) and bovine parainfluenza 3 virus (PI3V), to reduce the quality and duration of nasal excretion of both viruses.

Onset of immunity - 10days after vaccine

Duration of immunity - 12 weeks after vaccination